Skip to main content
main-content

SGLT2 inhibitors


Browse the latest news, expert commentary, and educational content on the SGLT2 inhibitor medication class.


Highlights

04-13-2021 | Dapagliflozin | News

DAPA-HF: Consistent benefits of dapagliflozin in men and women

Adding dapagliflozin to standard care improves outcomes for people with heart failure and reduced ejection fraction irrespective of sex, suggests a prespecified subgroup analysis of the DAPA-HF trial.

03-17-2021 | Dapagliflozin | News

Dapagliflozin may have primary prevention role for HF, renal outcomes

Post-hoc analysis of the primary prevention subgroup of DECLARE-TIMI 58 suggests that treatment with dapagliflozin may reduce the risk for first heart failure and renal events.

02-22-2021 | Canagliflozin | News

Antihypertensive effect for canagliflozin in diabetic renal disease

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

SGLT2 inhibitor use in type 2 diabetes management

Learn about prescribing these medications with guidance from the Improving Diabetes Steering Committee.

  • » A prescribing tool to inform prescribing decisions for SGLT2 inhibitors
  • » SGLT2 inhibitors: Key evidence and implications for clinical practice
  • » Translating SGLT2 inhibitor cardiovascular evidence into practice
  • » This content is intended only for UK healthcare providers and was made possible by educational funding provided by Napp Pharmaceuticals Ltd.

More on SGLT2 inhibitors

Stay informed with Medicine Matters

Get the latest developments in diabetes delivered straight to your inbox

Image Credits